Subgroups according to BASDAI/ASDAS category (baseline)

(PDF) Both Baseline Clinical Factors and Genetic Polymorphisms Influence the Development of Severe Functional Status in Ankylosing Spondylitis

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab

Frontiers Prediction of radiographic progression pattern in patients with ankylosing spondylitis using group-based trajectory modeling and decision trees

Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis

Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central–eastern Europe

Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort

Change in HAQ-S and SF-36 PCS by ASDAS classification Change in least

Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial - Fabian Proft, Anja Weiß, Murat Torgutalp, Mikhail Protopopov, Valeria Rios Rodriguez, Hildrun

Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study - Roberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, Salvatore D'Angelo, Antonio Marchesoni, Carlo Salvarani, Ennio Lubrano

Refining the Focus: A New Look at Spondylitis

ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy

Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central–eastern Europe